Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Legend Biotech (LEGN) Shares Outstanding (Diluted Average) (2019 - 2025)

Legend Biotech filings provide 6 years of Shares Outstanding (Diluted Average) readings, the most recent being $810.0 for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 68.75% to $810.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $810.0, a 68.75% increase, with the full-year FY2025 number at $810.0, up 68.75% from a year prior.
  • Shares Outstanding (Diluted Average) hit $810.0 in Q4 2025 for Legend Biotech, up from $720.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $308.7 million in Q1 2022 to a low of $210.0 in Q2 2024.
  • Median Shares Outstanding (Diluted Average) over the past 4 years was $810.0 (2025), compared with a mean of $106.3 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): plummeted 99.87% in 2021 and later skyrocketed 115824.18% in 2022.
  • Legend Biotech's Shares Outstanding (Diluted Average) stood at $293.2 million in 2021, then increased by 5.29% to $308.7 million in 2022, then crashed by 100.0% to $480.0 in 2024, then soared by 68.75% to $810.0 in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $810.0 (Q4 2025), $720.0 (Q3 2025), and $620.0 (Q2 2025) per Business Quant data.